Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379:753–63.
Google Scholar
Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.
Google Scholar
Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA. Ovarian cancer therapy: homologous recombination deficiency as a predictive biomarker of response to PARP inhibitors. Onco Targets Ther. 2022;15:1105–17.
Google Scholar
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102.
Google Scholar
Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31:1606–22.
Google Scholar
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094–108.
Google Scholar
Yap TA, Sandhu SK, Carden CP, De Bono JS. Poly(ADP-Ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA: A Cancer J Clin. 2011;61:31–49.
Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, et al. Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer. 2021;21:1154.
Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, et al. Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1/2 mutations or mutations in non-BRCA1/2, DNA damage repair genes. Clin Breast Cancer. 2022;22:319–25.
Google Scholar
Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764–75.
Google Scholar
Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, et al. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: a meta-analysis. Cancer. 2021;127:2432–41.
Google Scholar
Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 Breast Cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304–11.
Google Scholar
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, et al. Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1/ENGOT-ov25 trial. JCO Precis Oncol. 2023;7:e2200258.
Google Scholar
Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol. 2012;124:347–53.
Google Scholar
Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997;57:3347–50.
Google Scholar
Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis. 2000;21:147–51.
Google Scholar
Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, et al. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2014;73:771–8.
Google Scholar
Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne A-C, Lopez-Crapez E, et al. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer. 2013;13:523.
Google Scholar
Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients-a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). Eur J Cancer. 2014;50:2090–8.
Google Scholar
Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, et al. Constitutional Methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res. 2011;4:23–33.
Google Scholar
Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, et al. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2020;112:1190–203.
Google Scholar
Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, et al. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecol Oncol. 2019;153:217–22.
Google Scholar
Mikeska T, Candiloro IL, Dobrovic A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics. 2010;2:561–73.
Google Scholar
Lim AM, Candiloro ILM, Wong N, Collins M, Do H, Takano EA, et al. Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. Clin Epigenet. 2014;6:22.
Google Scholar
Kondrashova O, Topp M, Nesic K, Lieschke E, Ho G-Y, Harrell MI, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9:3970.
Google Scholar
Xu L, Liddell B, Nesic K, Geissler F, Ashwood LM, Wakefield MJ, et al. High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers. NAR Cancer. 2024;6.
Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP Inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7:984–98.
Google Scholar
Patch A-M, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole–genome characterization of chemoresistant ovarian cancer. Nature. 2015;521:489–94.
Google Scholar
Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021;12:2487.
Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, et al. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. Sci Transl Med. 2022;14:eabn1926.
Google Scholar
Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32:240–9.
Google Scholar
Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, et al. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Res Treat. 2020;181:323–9.
Google Scholar
Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho G-Y, et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma. Cancer Res. 2021;81:4709–22.
Google Scholar
Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel Taylor M, Kelly Rebecca L, et al. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer. 2021;3:zcab028.
Kawazu M, Kojima S, Ueno T, Totoki Y, Nakamura H, Kunita A, et al. Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency. PLoS Genet. 2017;13:e1006853.
Google Scholar
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, et al. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov. 2021;11:2796–811.
Google Scholar
Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, et al. Exquisitely platinum-sensitive triple-negative breast cancer, time for BRCA methylation testing? JCO Prec Oncol. 2022;6:e2200309.
Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103:334–46.
Google Scholar
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a Germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244–50.
Google Scholar
Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharm. 2005;5:388–93.
Google Scholar
Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, et al. BRCA1 CpG Island hypermethylation predicts sensitivity to Poly(Adenosine Diphosphate)- ribose polymerase inhibitors. J Clin Oncol. 2010;28:e563–e4.
Google Scholar
Fink JL, Jaradi B, Stone N, Sanker B, Zhang F, Dobrovic A, et al. Validation and performance of quantitative BRCA1 and RAD51C promoter hypermethylation testing in breast and ovarian cancers. J Mol Diagn. 2025;27:139–53.
Google Scholar
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. nature. 2013;500:415–21.
Google Scholar
Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16:475.
Google Scholar
Pitiyarachchi O, Lee YC, Sim H-W, Srirangan S, Mapagu C, Kirk J, et al. Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. Transl Oncol. 2023;31:101638.
Google Scholar
Wojdacz TK, Møller TH, Thestrup BB, Kristensen LS, Hansen LL. Limitations and advantages of MS-HRM and bisulfite sequencing for single locus methylation studies. Expert Rev Mol Diagn. 2010;10:575–80.
Google Scholar
Wong EM, Dobrovic A. Assessing gene-specific methylation using HRM-based analysis. In: Park D, ed. PCR Protocols. Method in Molecular Biology, 2011;687:207–17.
Wojdacz TK, Dobrovic A, Hansen LL. Methylation-sensitive high-resolution melting. Nat Protoc. 2008;3:1903–8.
Google Scholar
Tan TJ, Sammons S, Im Y-H, She L, Mundy K, Bigelow R, et al. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2024;30:1240–7.
Google Scholar
Lee CK, Kartikasari AER, Bound NT, Francis KE, Shield-Artin K, Bedo J, et al. Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial. Nat Commun. 2025;16:9756.
Google Scholar
GCIG: Gynecologic Cancer Intergroup. GCIG CA 125 Response Definition 2005. Available from: http://www.gcig.igcs.org/CA125/respdef_nov2005.pdf. Accessed Dec 2015.
Team RC. R: A language and environment for statistical computing. Vienna, Austria. : R Foundation for Statistical Computing; 2023.
Ngu S-F, Ngan HY, Chan KK. A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report. Cancer Drug Resistance. 2022;5:662.
Google Scholar
Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, et al. Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. Ann Oncol. 2020;31:822–3.
Google Scholar
Kahn RM, Selenica P, Boerner T, Roche KL, Xiao Y, Sia TY, et al. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: analysis of tumor phenotype and survival. Gynecologic Oncol. 2024;180:35–43.
Google Scholar
